State-Matched Lipid Nanoparticle Delivery for Sustained Activator Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods face challenges in maintaining and enhancing the effect of activators in target cells, particularly when multiple rounds of delivery are required, leading to difficulties in achieving sufficient activity and observable effects.
Innovation Solution
A method involving the sequential use of lipid nanoparticles with tailored lipid compositions to match the changing states of target cells, encapsulating different activators to maintain and enhance the effect of activators by adjusting the affinity of lipid nanoparticles to the specific states of the cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional gene delivery methods are used with fixed lipid composition, then initial delivery efficiency is achieved, but the effect of activator cannot be maintained or enhanced over multiple delivery rounds
Solution Approach 1:
The patent applies dynamics by making the lipid nanoparticle composition adaptable and changeable over time. Different lipid compositions are used in sequential delivery rounds to match the changing physiological states of target cells. The lipid composition is dynamically adjusted based on cell state markers, enabling the delivery system to adapt to evolving cellular conditions and maintain activator effectiveness across multiple delivery cycles.
Solution Approach 2:
The patent implements parameter changes by modifying the lipid composition parameters (such as lipid ratio, charge, and physical properties) according to the target cell's physiological state. By changing these parameters in response to cell state transitions, the delivery system optimizes its affinity and uptake efficiency at each delivery stage, thereby sustaining and enhancing activator effects over time.
2Productivity
If multiple rounds of gene delivery are performed with the same lipid composition, then delivery protocol simplicity is maintained, but delivery efficiency decreases in subsequent rounds
Solution Approach 1:
The patent changes the lipid composition parameters between delivery rounds to restore delivery efficiency. By adjusting parameters such as lipid charge, hydrophobicity, and molecular structure based on the target cell's physiological state at each stage, the system overcomes tolerance and uptake saturation issues that arise from repeated identical deliveries, thereby maintaining high productivity across multiple rounds.
Solution Approach 2:
The patent segments the delivery protocol into distinct phases, each with optimized lipid compositions tailored to specific cell states. This segmentation allows each delivery round to be independently optimized for maximum efficiency while adapting to progressive cellular changes, transforming a single rigid protocol into a flexible multi-stage approach.
3Reliability
If lipid nanoparticle affinity is optimized for initial cell state, then initial uptake efficiency is maximized, but effectiveness decreases as cells transition to different states
Solution Approach 1:
The patent employs dynamic adaptation by adjusting lipid nanoparticle properties to match the evolving physiological state of target cells. The lipid composition is modified in response to cell state transitions, ensuring continuous optimal affinity and uptake efficiency throughout the treatment process, thereby maintaining reliable activator effects despite cellular changes.
Solution Approach 2:
The patent applies local quality by tailoring specific lipid composition characteristics to match the requirements of different cell states. Each delivery round uses lipid nanoparticles with properties specifically optimized for the prevailing cellular condition, such as adjusting charge density or hydrophobicity to match membrane properties at that particular stage, thereby ensuring reliable delivery across state transitions.
Data Source
AI summary
According to one embodiment, a method is for maintaining and/or enhances the effect of an activator in a target cell. The method includes bringing a target cell in a first state into contact with a first lipid nanoparticle encapsulating a first activator, generating a target cell in a second state from the target cell in the first state, bringing a second lipid nanoparticle encapsulating a second activator into contact with the target cell in the second state, generating a target cell in a third state from the target cell in the second state, and maintaining and/or enhancing the effect of the activator in the target cell. Each of the first and second lipid nanoparticles is designed to exhibit an affinity appropriate for the corresponding target cell.